Business
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
-- Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n-- Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor in patients with multiple myeloma will be presented as a poster at the 2021 American Society of Hematology (ASH) Annual Meeting on December 13, 2021 --\n\n-- MGTA-117 targeted conditioning program clinical trial start-up activities are ongoing after clearance of Investigational New Drug (IND) Application; Phase 1/2 trial expected to open in December 2021 --\n\n-- Ended Q3 2021 with approximately $192.6 million in cash, cash equivalents and marketable securities, and the company maintains guidance that cash reserves are expected to fund the operating plan into Q3 2023 --\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the third quarter ended September 30, 2021, and recent program highlights.\n\n“We are pleased with our recent execution across the portfolio as we look to continue to allocate our capital efficiently to our value-creating opportunities,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “In mid-September, we cleared the IND process for the MGTA-117 targeted conditioning program and are now conducting the clinical trial start-up activities with the continued expectation of opening the trial this year. The MGTA-145 stem cell mobilization program also continues to advance with a fully enrolled investigator-initiated trial in multiple myeloma patients, a Phase 2 clinical trial in allogeneic transplant and the expected start of a Phase 2 clinical trial evaluating mobilization and collection of stem cells from patients with sickle cell disease.”\n\nBusiness Highlights:\n\nIn October 2021, Magenta welcomed Jeffrey Humphrey, M.D. to its Executive Team as Chief Medical Officer.\n\nProgram Highlights:\n\nMGTA-145 Stem Cell Mobilization and Collection\n\nRecent and Planned Activity:\n\nAutologous Stem Cell Transplant: Multiple Myeloma\n\n\nInvestigator-Initiated Phase 2 Clinical Trial Design, Topline Data and Next Steps.\n\n\nTrial Design: Surbhi Sidana, M.D., Assistant Professo...